Form 4 for GILD Gilead Sciences
Accepted 2025-03-12 00:00:00 ET · period of report 2025-03-10 · accession 0001127602-25-009293 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-03-12 | 2025-03-10 | GILD | O'Day Daniel Patrick | COB, CEO, Dir | M - OptEx | — | +24.0K | 641.9K | +4% | — |
| D | 2025-03-12 | 2025-03-10 | GILD | O'Day Daniel Patrick | COB, CEO, Dir | F - Tax | $117.21 | -11.6K | 630.3K | -2% | -$1.36M |
| D | 2025-03-12 | 2025-03-10 | GILD | O'Day Daniel Patrick | COB, CEO, Dir | M - OptEx | — | -24.0K | 81.0K | -23% | — |
| DM | 2025-03-12 | 2025-03-10 | GILD | O'Day Daniel Patrick | COB, CEO, Dir | A - Grant | $0.00 | +208.1K | 119.3K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-10 | M | A | 24,024 | — | 641,900 | D | — | — | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. |
| 2 | Common | Common Stock | 2025-03-10 | F | D | 11,632 | $117.21 | 630,268 | D | — | — | |
| 3 | Derivative | Restricted Stock Unit | 2025-03-10 | M | D | 24,024 | — | 80,953 | D | — · — to — | 24,024 Common Stock | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. (F2) The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
| 4 | Derivative | Non-qualified Stock Option (Right to Buy) | 2025-03-10 | A | A | 169,690 | $0.00 | 169,690 | D | $117.21 · — to 2035-03-10 | 169,690 Common Stock | (F3) The options have a four-year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
| 5 | Derivative | Restricted Stock Unit | 2025-03-10 | A | A | 38,395 | — | 119,348 | D | — · — to — | 38,395 Common Stock | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. (F2) The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |